New use possible for Lilly’s Evista

Eli Lilly and Co. may have found a new use for its osteoporosis drug Evista, according to Bloomberg.

The U.S. Food and Drug Administration said Evista reduced the risk of certain invasive breast cancers in post-menopausal women.

However, studies from Indianapolis-based Lilly provided weaker support for Evista’s ability to help women at high risk of developing breast cancer, the FDA said.

Evista is a $1 billion a year drug, but Lilly wants to find new uses for it because analysts expect its sales to tail off gradually over the next several years. Lilly has a patent on Evista until 2014.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}